La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Human Metabolome Technologies Bilan de santé

Santé financière contrôle des critères 5/6

Human Metabolome Technologies possède un total de capitaux propres de ¥1.9B et une dette totale de ¥200.0M, ce qui porte son ratio d'endettement à 10.4%. Son actif total et son passif total sont ¥2.5B et de ¥565.0M. L'EBIT de Human Metabolome Technologies est ¥200.0M ce qui fait que son ratio de couverture des intérêts 100. Elle dispose de liquidités et de placements à court terme de ¥1.7B.

Informations clés

10.4%

Ratio d'endettement

JP¥200.00m

Dette

Ratio de couverture des intérêts	100x
Argent liquide	JP¥1.65b
Fonds propres	JP¥1.93b
Total du passif	JP¥565.00m
Total des actifs	JP¥2.49b

Mises à jour récentes de la santé financière

Recent updates

Human Metabolome Technologies, Inc.'s (TSE:6090) Business And Shares Still Trailing The Market

Aug 06

Human Metabolome Technologies (TSE:6090) Is Increasing Its Dividend To ¥15.00

Jun 07

Human Metabolome Technologies (TSE:6090) Is Increasing Its Dividend To ¥15.00

May 22

Human Metabolome Technologies (TSE:6090) Is Paying Out A Larger Dividend Than Last Year

Apr 06

Human Metabolome Technologies (TSE:6090) Is Increasing Its Dividend To ¥15.00

Mar 23

Human Metabolome Technologies (TSE:6090) Will Pay A Larger Dividend Than Last Year At ¥15.00

Feb 26

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de 6090 ( ¥2.1B ) dépassent ses passifs à court terme ( ¥534.0M ).

Passif à long terme: Les actifs à court terme de 6090 ( ¥2.1B ) dépassent ses passifs à long terme ( ¥31.0M ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: 6090 dispose de plus de liquidités que de sa dette totale.

Réduire la dette: Le ratio d'endettement de 6090 est passé de 0% à 10.4% au cours des 5 dernières années.

Couverture de la dette: La dette de 6090 est bien couverte par le flux de trésorerie opérationnel ( 128% ).

Couverture des intérêts: Les paiements d'intérêts de 6090 sur sa dette sont bien couverts par l'EBIT ( 100 x couverture).

Human Metabolome Technologies Bilan de santé

Santé financière contrôle des critères 5/6

Informations clés

Mises à jour récentes de la santé financière

Human Metabolome Technologies, Inc. Common Stock to Be Deleted from OTC Equity

Recent updates

Human Metabolome Technologies, Inc., Annual General Meeting, Sep 20, 2024

Human Metabolome Technologies, Inc.'s (TSE:6090) Business And Shares Still Trailing The Market

Investor sentiment deteriorates as stock falls 21%

Now 20% undervalued after recent price drop

Upcoming dividend of JP¥15.00 per share

Human Metabolome Technologies (TSE:6090) Is Increasing Its Dividend To ¥15.00

Human Metabolome Technologies, Inc. to Report Fiscal Year 2024 Results on Aug 09, 2024

Human Metabolome Technologies (TSE:6090) Is Increasing Its Dividend To ¥15.00

Third quarter 2024 earnings released: EPS: JP¥26.54 (vs JP¥26.07 in 3Q 2023)

Human Metabolome Technologies (TSE:6090) Is Paying Out A Larger Dividend Than Last Year

Human Metabolome Technologies, Inc. to Report Q3, 2024 Results on May 15, 2024

Human Metabolome Technologies (TSE:6090) Is Increasing Its Dividend To ¥15.00

Human Metabolome Technologies (TSE:6090) Will Pay A Larger Dividend Than Last Year At ¥15.00

Second quarter 2024 earnings released: EPS: JP¥18.43 (vs JP¥15.41 in 2Q 2023)

Dividend of JP¥15.00 announced

Human Metabolome Technologies, Inc. to Report Q2, 2024 Results on Feb 14, 2024

First quarter 2024 earnings released: JP¥6.43 loss per share (vs JP¥2.88 loss in 1Q 2023)

Human Metabolome Technologies, Inc. to Report Q1, 2024 Final Results on Nov 10, 2023

New major risk - Earnings quality

Full year 2023 earnings released: EPS: JP¥48.27 (vs JP¥45.25 in FY 2022)

Human Metabolome Technologies, Inc., Annual General Meeting, Sep 22, 2023

Human Metabolome Technologies, Inc. to Report Fiscal Year 2023 Results on Aug 10, 2023

Third quarter 2023 earnings released: EPS: JP¥26.07 (vs JP¥33.73 in 3Q 2022)

Second quarter 2023 earnings released: EPS: JP¥15.41 (vs JP¥22.03 in 2Q 2022)

Human Metabolome Technologies, Inc. to Report Q2, 2023 Results on Feb 14, 2023

Now 21% undervalued after recent price drop

First quarter 2023 earnings released: JP¥2.88 loss per share (vs JP¥8.14 loss in 1Q 2022)

First quarter 2023 earnings released: JP¥2.88 loss per share (vs JP¥8.14 loss in 1Q 2022)

Human Metabolome Technologies, Inc. Provides Consolidated Earnings Guidance for the Year Ending June 2023

Investor sentiment improved over the past week

Human Metabolome Technologies, Inc. to Report Q1, 2023 Results on Nov 11, 2022

Investor sentiment improved over the past week

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Human Metabolome Technologies, Inc., Annual General Meeting, Sep 22, 2022

Human Metabolome Technologies, Inc. Common Stock to Be Deleted from OTC Equity

Investor sentiment improved over the past week

Human Metabolome Technologies, Inc. to Report Fiscal Year 2022 Results on Aug 10, 2022

Investor sentiment improved over the past week

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Human Metabolome Technologies, Inc. Provides Earnings Guidance for the Full Year Ending June 2022

Insufficient new directors

Human Metabolome Technologies, Inc. to Report Q3, 2022 Results on May 13, 2022

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Human Metabolome Technologies, Inc. Provides Consolidated Earnings Guidance for the Year Ending June 30, 2022

First quarter 2022 earnings released: JP¥8.14 loss per share (vs JP¥6.11 loss in 1Q 2021)

Third quarter 2021 earnings released: EPS JP¥16.96 (vs JP¥22.98 loss in 3Q 2020)

Second quarter 2021 earnings released: EPS JP¥4.92 (vs JP¥22.98 loss in 2Q 2020)

New 90-day high: JP¥999

Human Metabolome Technologies, Inc. to Report Q2, 2021 Results on Feb 12, 2021

New 90-day low: JP¥741

New 90-day low: JP¥860

Human Metabolome Technologies, Inc. to Report Q1, 2021 Results on Nov 11, 2020

Human Metabolome Technologies, Inc. to Report Fiscal Year 2020 Results on Aug 14, 2020

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Découvrir des entreprises saines